- Walgreens partners with United Nations Foundation's Shot@Life campaign
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- PhRMA report lists 271 vaccines in development
- Study: Whooping cough vaccine may not prevent infection
- Study: Pharmacist intervention improves shingles vaccine rate
SWIFTWATER, Pa. — Sanofi’s vaccines division has won Food and Drug Administration approval for a vaccine designed for injection into the skin, the company said Tuesday.
Sanofi Pasteur announced the FDA approval of Fluzone Intradermal (influenza virus vaccine), which injects the vaccine into the skin via a short, fine needle, also known as a microinjection.
“The microinjection delivery system utilized in Fluzone Intradermal vaccine provides reliable and easy delivery of the vaccine into the dermal layer of the skin, an attractive site for immunization,” Sanofi Pasteur president and CEO Olivier Charmeil said. “Sanofi Pasteur is proud to bring this innovation in influenza vaccine administration to the U.S., offering healthcare providers a new tool that may help enhance adult influenza immunization rates.”